We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
You know the one entitled "Breakthrough clinical results"? Comparing the standard blood CtDna analysis currently offered by the likes of Illumina/Thermo Fisher to the analysis of the circulating tumour cells (obtained using Angle's Parsortix machine) from the same tube of blood was interesting, surely? The results indicated in some cases if the circulating tumour cells were not also analysed then important information could be MISSED. I think that is rather important. Do you agree? I don't quite see how you could not agree! Have a think about that one.
EC.
Or maybe these are simply existing jobs and they are recruiting to replace leavers.
"ANGLE has established a CTC harvest and analysis service from our UK-based Clinical Laboratory based in Guildford for customers worldwide. In alignment with company priorities, we plan to rapidly expand our services to include molecular profiling of CTCs and ctDNA using digital PCR and NGS to add to our image-based assays."
TwoGood2Die.
If Angle are doing so badly as you appear to want people to believe then why are they advertising for a purchasing assistant and a Warehouse/Stores operator? Don't tell me...... it's a ruse to improve the sp!! LOL!
Https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0138032
Everyone should give it a rest on umpteen quotes on 'research' use of Parsortix what matters is roll out of Parsortix for actual live 'testing'..
All these copy and paste citing research use are pretty meaningless what matters is commercial sales without which no traction and hence growth will occur.
I'm not saying that 'research' quotes arn't helpful but it's drowning out dialogue on AGL's future commercial prospects because if you can't sell any machines you don't have a future commercial strategy.
As mentioned earlier Parsortix is FDA approved for 'testing' breast cancer do why arn't we seeing any global sales growth in this area for Parsortix sales?
Https://biblio.ugent.be/publication/01HVRMR53RQ0R4Z1PFARV8B9XF
I can't download the whole text. The aim of the research appears to have been to establish methods of increasing further the efficiency of parsortix when dealing with certain types of pancreatic cancer. University of Ghent
Https://www.clinicaltrials.gov/study/NCT05648240?term=parsortix&rank=7
Something is brewing?
Perhaps the US show went well and fruited some deals?
Https://scholarshipdb.net/jobs-in-France/Precision-Medicine-Strategies-For-Patients-With-Metastases-Of-Colorectal-Carcinoma-Resistant-To-Treatments-Crcm=uf0D5-L87hGUZAAlkGUTnw.html
Team in France working on precision medicine who mention they use Parsortix
Current sp to have any chance of succeeding IMHO. As you point out with further funding there is no reason why the Parsortix technology could not get FDA clearance for medical use with cancers other than breast thus increasing the available market by something like 90%. I hasten to add the existing Breast cancer market combilned with the enourmous cancer drug trials markets should be easily enough for Angle Plc as it stands. To get a bid Angle need a decent sized pharma Co. to realise the potential here.
All IMHO.
Doesn't look like Astra Zenica are in any hurry to buy AGL at a mere £30m no doubt its the lack of full FDA approval for Parsortix to test the majority of cancers that's the deciding factor here!
Years away from any commercialisation I would suggest.
Gawdhelpus !
According to a Biotech manager in a radio 4 interview a day or two (6AM) and never repeated during the day as far as I am aware said, over the past 20 years very few companies had reached the main market and that Aim was no longer doing the job for which it was intended due to the main markets lack of interest. Another factor was lack of awareness which is certainly true for AGL - I did not see nor heard nor read any mention of AGLs FDA approval in the media. I presume companies do issue a press release when they have some really good news so how are investors to invest when they do not know of its existance.
Trials by using Angle's Parsortix machine to catch the circulating tumour cells for testing. Potentially there may also be a massive market for testing the patients circulating tumour cells to see if they are suitable for the Immunotherapy treatment in the first place.
https://en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors
All IMHO.
Yep, just a few posts a month would be healthier as cash dwindles
EC
This BB is for discussing the business prospects and not for spamming the BB day in day out.
You don't add any new material it's just long winded copy and paste and given the sheer lack of replies no one is interested.
Equally posting 'share price up 4%' it's just really bizarre behaviour!
Carrot
"You really need to stop posting complete and utter rubbish on this bb " - as opposed to half understood chunks of c&p?
Pots and kettles perhaps?
Up 4%.
TwoGood2Die. Clearly you did not look at the presentation (see link below). You really need to stop posting complete and utter rubbish on this bb and actually look at the presentations. Then you might post something that is actually true and is based on fact not complete fiction>>:-
The research side enables the monitoring of both HER2 and PD-L1 proteins using the Parsortix system to catch circulating tumour cells to test. You comments inferring they don't have enough potential clients are utterly ridiculous. HER2 and PL-L1 are proteins that can be targeted by modern Immunotherapy drugs. As you know unlike some other systems these cancer cells Parsortix catches are 99% alive and intact, ideal for analysing/testing. These Companies like AstraZeneca desperately need more feedback from their Immunotherapy drug trials involving HER2 and PD-L1. Although in some cases the drugs work extremely well sometimes, they don't and there is no *****conclusive proof***** as to why. For HER2 it is suspected the cancers status sometimes changes from HER2 positive to negative thus evading the targeted treatment. Same story with PD-L1. Using Parsortix these drug trial Companies could have the ability to monitor the HER2 and PD-L1 status of these proteins before, during and after a drug treatment. This could give invaluable information going forward to the Companies doing the trials. Look at the presentation (see link below) 13 mins 20 sec in. Mr Newland explains this top 100 Japanese Company (Eisal Inc.) with revenues over $4 BILLION and 80 active oncology trials involving more than 60,000 participants have contracted Angle to do a pilot study. I suggest they are on the ball and the first of many Companies that will use Parsortix to further their knowledge about the drug that have developed. In time Parsortix could be used at cancer clinics to find out which patients are most suitable for these treatments and which ones are not. Huge potential.
https://www.youtube.com/watch?v=cnQ6M05BiBY
https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/
Reply
Up 4%.
large trade to appear later.
Probably!
EC
Only volume sales occur when Parsortix is fully validated by the FDA until that point research use only has very limited revenue generation potential and hence low cash yield. Thats why Angle are heading for a cash placement.
However you want to slice and dice things it amounts to the same thing without validation there's no commercial traction through Parsortix machine sales.
Proteins using the Parsortix system to catch circulating tumour cells to test. You comments inferring they don't have enough potential clients are utterly ridiculous. HER2 and PL-L1 are proteins that can be targeted by modern Immunotherapy drugs. As you know unlike some other systems these cancer cells Parsortix catches are 99% alive and intact, ideal for analysing/testing. These Companies like AstraZeneca desperately need more feedback from their Immunotherapy drug trials involving HER2 and PD-L1. Although in some cases the drugs work extremely well sometimes, they don't and there is no *****conclusive proof***** as to why. For HER2 it is suspected the cancers status sometimes changes from HER2 positive to negative thus evading the targeted treatment. Same story with PD-L1. Using Parsortix these drug trial Companies could have the ability to monitor the HER2 and PD-L1 status of these proteins before, during and after a drug treatment. This could give invaluable information going forward to the Companies doing the trials. Look at the presentation (see link below) 13 mins 20 sec in. Mr Newland explains this top 100 Japanese Company (Eisal Inc.) with revenues over $4 BILLION and 80 active oncology trials involving more than 60,000 participants have contracted Angle to do a pilot study. I suggest they are on the ball and the first of many Companies that will use Parsortix to further their knowledge about the drug that have developed. In time Parsortix could be used at cancer clinics to find out which patients are most suitable for these treatments and which ones are not. Huge potential.
https://www.youtube.com/watch?v=cnQ6M05BiBY
https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/
yeah breast cancer is such a niche market isn’t it.
you got sacked for being a ******, doesn’t look like you’ve learned from the episode. shame your kids are being left to run feral whilst you log on to announce a placing and celebrate the spread of cancer.
EC
It's a fundamental question without FDA approval you don't have business there is only a limited number of opportunities to sell the Parsortix machine to labs to use it for 'research' purposes only.
Widescale lab adoption will only take place when labs receive a product that is ideally fully FDA approved to 'test' most if not all major cancer groups without which AGL will never generate sufficent revenues to breakeven let alone generate profits.
To me this discussion is fairly unimportant. Angle have FDA approval for hospitals using the Parsortix machine to catch circulating tumour cells (CTC's) from a blood sample from someone with metastasized breast cancer to get the HER2 status of the cancer etc.......... That market World wide is more than enough on it's own. I'm far more interested in the last announcement which basically says the partnership with Bioview to develop an automated CTC HER2 assay which uses A.I. is coming along nicely. PD-L1 to follow looks logical does it not............................................................?
https://www.lse.co.uk/rns/AGL/parsortix-her2-assay-showcased-at-aacr-2024-4k393y7ivsvtwno.html